

IN THE CLAIMS:

Claims 1-9 (canceled)

Claim 10 (currently amended): A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF or an antigenic determinant thereof.

Claim 11 (currently amended): A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF or an antigenic determinant thereof.

Claim 12 (currently amended): A method of co-inhibiting B-cell growth and immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF or an antigenic determinant thereof.

Claim 13 (currently amended): A method of inhibiting dendritic cell-induced B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF or an antigenic determinant thereof.

Claims 14-15 (canceled)

Claim 16 (original): The method according to claims 10-13, wherein the anti-BAFF receptor antibody is a monoclonal antibody.

Claims 17-50 (canceled)